Transcriptomics

Dataset Information

0

Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma


ABSTRACT: The use of Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib has achieved a remarkable clinical response in mantle cell lymphoma (MCL). Acquired drug resistance, however, is significant and impacts long-term survival of MCL patients. Here we demonstrate that DNMT3A is involved in ibrutinib resistance. We found that DNMT3A expression is upregulated upon ibrutinib treatment in ibrutinib-resistant MCL cells. Genetic and pharmacological analyses revealed that DNMT3A mediates ibrutinib resistance independent of its DNA-methylation function. Mechanistically, DNMT3A induces the expression of MYC target genes through interaction with the transcription factors MEF2B and MYC, thus mediating metabolic reprogramming to oxidative phosphorylation (OXPHOS). Targeting DNMT3A by a low dose of decitabine inhibits the growth of ibrutinib-resistant lymphoma cells both in vitro and in a patient-derived xenograft mouse model. These findings suggest that targeting DNMT3A-medited metabolic reprogramming to OXPHOS with decitabine provides a potential therapeutic strategy to overcome ibrutinib resistance in relapsed/refractory MCL.

ORGANISM(S): Homo sapiens

PROVIDER: GSE227976 | GEO | 2024/02/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-10-26 | PXD005734 | Pride
2015-12-31 | E-GEOD-70651 | biostudies-arrayexpress
2024-09-24 | GSE243395 | GEO
2023-12-06 | GSE223150 | GEO
2015-12-31 | GSE70651 | GEO
2016-07-15 | E-GEOD-70926 | biostudies-arrayexpress
2018-07-10 | GSE116810 | GEO
2016-07-15 | E-GEOD-70910 | biostudies-arrayexpress
2019-01-25 | PXD010568 | Pride
2021-04-26 | GSE141335 | GEO